Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

AMER MEDICAL ASSOC

1. Swiss National Science Foundation [3200B0-108176/1, PZOOP3_161146]
2. Roche Foundation for Anemia Research
3. Matching Fund of the Medical Faculty, University of Zurich
4. University Hospital Zurich